NCT Number: NCT00136253
Overcoming Nutritional Barriers in Hemodialysis Patients
American hemodialysis patients are frequently malnourished. This contributes to dialysis patient mortality rates that are the highest in the industrialized world at 22% per year. Poor nutritional status probably also contributes to high health care costs (an average of two hospitalizations annually per patient and total Medicare expenditures of $11 billion per year) and diminished quality of life. The researchers' prior work identified several potentially modifiable nutritional barriers (e.g. poor appetite, inadequate dialysis dose, poor nutritional knowledge, low fluid intake, and needing help shopping and cooking) and pilot tested a promising approach to overcome these barriers.
This proposed community-based randomized controlled trial extends the researchers' prior work by targeting specific nutritional barriers with a tailored feedback and education intervention. Approximately 40 dialysis facilities in northeast Ohio will be randomly assigned to intervention and control groups, with approximately 100 malnourished patients enrolled from 20 intervention facilities and 100 from 20 control facilities. Baseline evaluation will include measures of nutritional status, specific barriers, inpatient expenditures, and quality of life. On a monthly basis for 12 months, intervention patients and their dietitians will receive tailored feedback and education on overcoming patient-specific barriers. They will then meet monthly to jointly formulate a care plan addressing these barriers. Control patients will continue to get usual care. Major analyses will compare changes in nutritional parameters in intervention vs. control patients with adjustment for nesting of patients within facilities.
The proposed project will test a novel intervention that targets patients and providers as they together make nutrition-related decisions. Overcoming specific barriers may lead not only to improved nutritional status but also to better patient survival, decreased health care costs, and increased quality of life.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Most recent albumin and mean albumin over last 3 months <3.7 g/dL by bromcresol green method (or <3.4 g/dL by bromcresol purple method)
- Age greater than or equal to 18 years
- On chronic hemodialysis at least 9 months
Exclusion criteria
- Mentally incompetent
- Cirrhosis
- AIDS
- Cancer
- Terminal illness
- Malabsorption
- Receiving total parenteral nutrition
Treatment and study plan
Primary outcomes
-
Change in albumin
-
Change in albumin of 0.20 or greater and survival
Secondary outcomes
-
Change in subjective global assessment, weight, dietary intake, specific nutritional barriers
Sponsors and collaborators
Lead sponsor
Case Western Reserve University
Other
Registry information
Important dates
- Study start
- 2002
- Study completion
- 2004
- First posted
- Aug 29, 2005
- Registry last updated
- Dec 13, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Association of Middle Molecules Clearance With HDF Volume
NCT06515899
Chronic Disease, Disease Attributes
Stevenage, Hertfordshire, United Kingdom
View Trial DetailsVIRTUUS Children's Study
NCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsSafety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
NCT04817774
Chronic Disease, Disease Attributes
Leuven, Belgium
View Trial DetailsCommunication During Hospitalization About Resuscitation Trial
NCT02984124
Chronic Disease, Disease Attributes
Chapel Hill, North Carolina, United States
View Trial Details